1,418 Shares of Eli Lilly and Company $LLY Purchased by OPTIMAS CAPITAL Ltd

OPTIMAS CAPITAL Ltd purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,418 shares of the company’s stock, valued at approximately $1,641,000. Eli Lilly and Company accounts for approximately 2.2% of OPTIMAS CAPITAL Ltd’s investment portfolio, making the stock its 14th largest holding.

Several other hedge funds also recently added to or reduced their stakes in LLY. Bank of America Corp DE bought a new stake in Eli Lilly and Company in the second quarter worth about $13,522,666,000. Jupiter Topco LLC purchased a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $4,667,180,000. Fifth Third Bancorp boosted its position in shares of Eli Lilly and Company by 321.3% during the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock valued at $1,805,959,000 after buying an additional 1,497,423 shares during the period. Corient Private Wealth LP bought a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $764,116,000. Finally, BlackRock Inc. grew its stake in shares of Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after buying an additional 1,046,558 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $17,020,770 in the last ninety days. 0.14% of the stock is owned by company insiders.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through Hims & Hers’ telehealth platform. Eligible patients with a prescription can access Lilly’s self-pay prices—reportedly starting at $149—without leaving the platform. The deal could widen patient access and Lilly’s reach in the competitive obesity-treatment market. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
• Positive Sentiment: New Phase 3 results for investigational retatrutide showed substantial reductions in weight and knee pain among adults with obesity and knee osteoarthritis. Lilly also reported positive Phase 3b results for combining Taltz and Zepbound in people with psoriatic arthritis and obesity, supporting the potential of its medicines in additional patient groups. Lilly to showcase new retatrutide, Taltz and Zepbound data
• Negative Sentiment: Price competition across the GLP-1 market remains a risk to Lilly’s growth and drug margins, as branded treatments compete with lower-priced options and providers seek self-pay patients. Eli Lilly’s GLP-1 franchise faces growing price competition

Analyst Upgrades and Downgrades

LLY has been the topic of several recent analyst reports. Morgan Stanley increased their price target on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Royal Bank Of Canada boosted their price objective on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an “outperform” rating in a report on Friday, October 30th. Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Guggenheim upped their price objective on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research report on Friday, September 18th. Finally, JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,404.14.

Eli Lilly and Company Trading Up 0.5%

Eli Lilly and Company stock traded up $7.42 during trading hours on Friday, hitting $1,372.15. The company had a trading volume of 3,802,992 shares, compared to its average volume of 2,624,130. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The firm has a market cap of $1.29 trillion, a P/E ratio of 44.54, a P/E/G ratio of 1.77 and a beta of 0.40. The company has a 50-day moving average price of $1,215.24 and a two-hundred day moving average price of $1,101.16. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,453.00.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. During the same period last year, the company posted $7.02 earnings per share. The company’s quarterly revenue was up 38.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Eli Lilly and Company will post 35.70 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is 22.46%.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.